JP2004532266A - 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体 - Google Patents

心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体 Download PDF

Info

Publication number
JP2004532266A
JP2004532266A JP2003500073A JP2003500073A JP2004532266A JP 2004532266 A JP2004532266 A JP 2004532266A JP 2003500073 A JP2003500073 A JP 2003500073A JP 2003500073 A JP2003500073 A JP 2003500073A JP 2004532266 A JP2004532266 A JP 2004532266A
Authority
JP
Japan
Prior art keywords
methyl
compound according
thiazol
ylcarbonyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532266A5 (https=
Inventor
デュメイトル，ベルナール，アンドレ
ゴスミニ，ロマン，リュック，マリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2004532266A publication Critical patent/JP2004532266A/ja
Publication of JP2004532266A5 publication Critical patent/JP2004532266A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003500073A 2001-05-31 2002-05-29 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体 Pending JP2004532266A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113233.1A GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds
PCT/EP2002/005885 WO2002096894A1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases

Publications (2)

Publication Number Publication Date
JP2004532266A true JP2004532266A (ja) 2004-10-21
JP2004532266A5 JP2004532266A5 (https=) 2005-12-22

Family

ID=9915638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003500073A Pending JP2004532266A (ja) 2001-05-31 2002-05-29 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体

Country Status (21)

Country Link
US (1) US6867225B2 (https=)
EP (1) EP1392665B1 (https=)
JP (1) JP2004532266A (https=)
KR (1) KR20040007633A (https=)
CN (1) CN1529698A (https=)
AT (1) ATE377007T1 (https=)
AU (1) AU2002312954B2 (https=)
BR (1) BR0210077A (https=)
CA (1) CA2448103A1 (https=)
CO (1) CO5540299A2 (https=)
CZ (1) CZ20033250A3 (https=)
DE (1) DE60223245T2 (https=)
ES (1) ES2295352T3 (https=)
GB (1) GB0113233D0 (https=)
HU (1) HUP0400056A2 (https=)
IL (1) IL158818A0 (https=)
MX (1) MXPA03010584A (https=)
NO (1) NO20035316D0 (https=)
PL (1) PL367215A1 (https=)
WO (1) WO2002096894A1 (https=)
ZA (1) ZA200308864B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
JP2008531662A (ja) * 2005-03-03 2008-08-14 ピエール、ファーブル、メディカマン １，２，４−トリアジン誘導体、その製造方法およびヒト治療におけるその使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
AU2003261935A1 (en) 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CA2744985C (en) 2008-12-01 2014-05-06 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring useful for the prevention or treatment of hyperlipidemia
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6207422B1 (en) * 1998-04-17 2001-03-27 The Metrohealth System Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
WO2000018903A2 (en) * 1998-09-29 2000-04-06 The Johns Hopkins University Inducible genetic suppression of cellular excitability
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531662A (ja) * 2005-03-03 2008-08-14 ピエール、ファーブル、メディカマン １，２，４−トリアジン誘導体、その製造方法およびヒト治療におけるその使用
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
JPWO2007126043A1 (ja) * 2006-04-27 2009-09-10 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途

Also Published As

Publication number Publication date
ZA200308864B (en) 2005-02-14
CZ20033250A3 (en) 2004-03-17
ES2295352T3 (es) 2008-04-16
NO20035316L (no) 2003-11-28
DE60223245D1 (de) 2007-12-13
BR0210077A (pt) 2004-06-22
AU2002312954B2 (en) 2004-12-02
PL367215A1 (en) 2005-02-21
GB0113233D0 (en) 2001-07-25
US20040176427A1 (en) 2004-09-09
HUP0400056A2 (hu) 2004-04-28
ATE377007T1 (de) 2007-11-15
US6867225B2 (en) 2005-03-15
NO20035316D0 (no) 2003-11-28
WO2002096894A1 (en) 2002-12-05
CN1529698A (zh) 2004-09-15
EP1392665A1 (en) 2004-03-03
DE60223245T2 (de) 2008-08-14
CA2448103A1 (en) 2002-12-05
MXPA03010584A (es) 2004-03-09
IL158818A0 (en) 2004-05-12
EP1392665B1 (en) 2007-10-31
CO5540299A2 (es) 2005-07-29
KR20040007633A (ko) 2004-01-24

Similar Documents

Publication Publication Date Title
JP2004532266A (ja) 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体
JP3884290B2 (ja) Ｈｐｐａｒアルファアクチベーターとしての置換オキサゾールおよびチアゾール誘導体
JP3490704B2 (ja) チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用
AU2002312954A1 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
JP2004518702A (ja) Ｐｐａｒ関連障害治療用のチアゾール誘導体
JP2004517100A (ja) ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
JP2005529965A (ja) ｈＰＰＡＲ活性化物質としてのフェニルオキシアルカン酸誘導体
KR100859591B1 (ko) Ｈｐｐａｒ-알파 수용체의 옥사졸/티아졸-유도체 활성제
AU2002317765A1 (en) Oxazol/ thiazol-derivatives activators of the hPPAR-alpha receptor
US7141591B2 (en) 1,2,4-oxadiazole derivatives as hPPAR alpha agonists
AU2002220902A1 (en) 1, 2, 4-oxadiazole derivatives as hPPAR alpha agonists
JP2007508270A (ja) Ｉ．ａ．ジスリピデミアの治療におけるｈｐｐａｒ作用物質として使用するためのチアゾール−２−カルボキシアミド誘導体
HK1064367B (en) Oxazol/thiazol-derivatives activators of the hppar-alpha receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090901